The effect of human growth hormone-releasing factor or porcine somatotropin on serum hormones and metabolites, growth performance and carcass traits in swine.

Forty barrows (77.9 +/- 5.5 kg BW) were allotted to one of five treatment groups to examine the effects of various doses of human growth hormone-releasing factor (1-44)NH2 (hGRF) or porcine somatotropin (pST) administered twice daily on serum hormones and metabolites, performance and carcass traits. Barrows were injected s.c. with either a placebo, 10 micrograms hGRF.kg BW-1.12 h-1, 20 micrograms hGRF.kg BW-1.12 h-1, 20 micrograms pST.kg BW-1.12 h-1 or 40 micrograms pST.kg BW-1.12 h-1 for a 36-d growth trial. Blood samples were collected from 13 barrows at intervals for 360 min after injection on d 21. Compared with the placebo, 10 micrograms hGRF.kg-1.12 h-1 increased (P less than .01) serum pST and insulin and decreased (P less than .001) urea N. Injecting 20 micrograms hGRF/kg.12 h-1 elevated (P less than .001) serum pST, insulin and insulin-like growth factor-I (IGF-I) but lowered (P less than .001) urea N. Exogenous pST increased (P less than .001) serum pST, insulin, IGF-I and glucose but decreased (P less than .001) urea N. Growth rate tended to increase, and feed intake and feed/gain decreased, in a dose-related manner in response to hGRF. Also, pigs receiving 10 or 20 micrograms hGRF.kg-1.12 h-1 had reduced (P less than .1) backfat and increased (P less than .1) loineye area and percentage lean in the ham compared with pigs receiving the placebo. At equal doses, pST elicited more dramatic improvements in performance and carcass criteria than did hGRF.(ABSTRACT TRUNCATED AT 250 WORDS)